Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
PYPD$5.60+3.32%
PolyPid Ltd.
Sector: Surgical & Medical Instruments & ApparatusIndustry: BiotechnologyCountry: ILExchange: Nasdaq
Mkt Cap:$116.84M
Float & O/S:
Inst Own:
DilutionScan read 56 of PolyPid Ltd.'s SEC filings and found 8 warrant series, 2 ATM programs and 5 shelf registrations on file for PYPD. The latest dilution event on file is ATM sales on Jul 31, 2026. Analysis updated Oct 6, 2026.
Signal8 Summary
PYPD
Pre-revenue biotech nearing FDA decision
Snapshot
PolyPid is a pre-revenue biotech with no product sales yet, losing $34.2M in FY 2025 on top of similar losses the two years before. It holds only $12.9M in cash, but recent milestone payments from a new partner reportedly push its funding into 2028.
What's Happening Right Now
- : On Aug 15, 2026, the FDA accepted PolyPid's NDA for D-PLEX100 with Priority Review, setting a PDUFA date of Nov 28, 2026 (about a quarter earlier than expected) and triggering a $15M milestone payment from partner Azurity.
- : On Aug 12, 2026, PolyPid reported a Q2 net loss of $7.8M ($0.35/share) and said the recent Azurity milestone payments extend its cash runway into 2028.
- : On Jul 21, 2026, PolyPid signed an exclusive deal with Azurity Pharmaceuticals to commercialize D-PLEX100 in the U.S. and Canada, worth $15M upfront plus up to $300M in milestones and royalties, with a targeted 2027 launch.
Raise routes on file: active ATM + effective shelf · latest dilution event 95 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Jul 31, 2026 · ATM Sale
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Outstanding
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2024
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
August 2024 Warrants at
Issued 2024
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
ATM program
Issued 2024
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
ATM program
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
F-3 shelf registration
Issued 2024
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
F-3 shelf registration
Issued 2025
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
F-3 shelf registration
Issued 2025
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
F-3 shelf registration
Issued 2024
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
F-3 shelf registration
Issued 2024
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
Know who's about to sell into your PYPD trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
